EUCTR2005-005423-34-IT进行中（未招募）不适用
A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment with Ropinirole Immediate Release IR Tablets or Ropinirole Prolonged Release / Extended Release PR/XR Tablets in Advanced Stage Parkinson s Disease Subjects who are not Adequately Controlled on L-dopa. - ND
GlaxoSmithKline R D0 个研究点目标入组 516 人开始时间: 2006年10月3日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 516
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Men or non-pregnant/non-breast-feeding women of at least 30 years of age at screening. Women of child-bearing potential must be practicing a clinically accepted method of contraception during the study and for at least one month prior to randomisation and one month following completion of the study. Acceptable contraceptive methods include oral contraception, surgical sterilization, intrauterine device IUD , or diaphragm IN ADDITION to spermicidal foam and condom on male partner, or systemic contraception i.e. Norplant System . 2.Diagnosis of idiopathic Parkinson s disease according to modified Hoehn Yahr criteria Stages II-IV and demonstrating lack of control with L-dopa therapy e.g. end of dose akinesia, simple on / off fluctuations . 3.Subjects receiving a stable dose of L-dopa for at least 4 weeks prior to Baseline Period. 4.Subjects provided written informed consent for the study. 5.A minimum of 3 hours awake time off for each diary day was recorded during the Baseline Period. 6.Subjects are willing and able to comply with study procedures, including diary card completion and follow-up clinic visits.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Late stage advanced subjects demonstrating incapacitating dyskinesias on their stable dose of L-dopa. 2.Presence, or history within the previous 3 months, of significant and/or uncontrolled psychiatric, haematological, renal, hepatic, endocrinological, neurological other than Parkinson s disease , or cardiovascular disease or active malignancy other than basal cell cancer . 3.Any abnormality, at screening, that the investigator deems to be clinically relevant on history, physical examination and in diagnostic laboratory tests including ECG. 4.Recent history of severe dizziness or fainting due to postural hypotension on standing. 5.Clinical dementia that in the judgment of the investigator would preclude assessment of the subject. 6.Subjects with neurotic behaviour, crippling degenerative arthritis or limb amputations, which would preclude efficacy or safety assessments. 7.Subjects with prior or current major psychosis e.g. schizophrenia or psychotic depression e.g., scoring 3 or 4 on UPDRS item 2 thought disorder or item 3 depression . 8.Recent history or current evidence of drug abuse or alcoholism. 9.Consumption of any dopamine agonist within 4 weeks of the screening visit. 10.Definite or suspected personal or family history of clinically significant adverse reactions or hypersensitivity to ropinirole or to drugs with a similar chemical structure that would preclude long-term dosing with ropinirole IR or PR/XR tablets. 11.Withdrawal, introduction, or change in dose of HRT and/or any drug known to substantially inhibit Cytochrome P 450 1A2 CYP1A2 e.g. ciprofloxacin, fluvoxamine, cimetidine, ethinyloestradiol or induce CYP1A2 e.g. tobacco, omeprazole within 7 days prior to enrolment. Subjects already on chronic therapy with any of these agents may be enrolled but must remain on stable doses of the agent from 7 days prior to enrolment through the end of the Treatment Period. 12.Use of an investigational drug from 30 days prior to enrolment through to the end of the Treatment Period. 13.More than 12 hours off time recorded on any individual day during the Baseline Period.
研究者
相似试验
进行中（未招募）
1 期
A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment with Ropinirole Immediate Release (IR) Tablets or Ropinirole Prolonged Release / Extended Release (PR/XR) Tablets in Advanced Stage Parkinson’s Disease Subjects who are not Adequately Controlled on L-dopa.Parkinson's diseaseEUCTR2005-005423-34-GBGlaxoSmithKline Research & Development Ltd
进行中（未招募）
不适用
A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects with Major Depressive DisorderMajor Depressive DisordersMedDRA version: 9.1Level: LLTClassification code 10057840Term: Major depressionEUCTR2004-004984-32-ITGLAXO SMITHKLINE500
进行中（未招募）
不适用
A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects with Major Depressive DisorderEUCTR2004-004984-32-SEGlaxoSmithKline Research and Development Limited348
已完成
3 期
A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Multicentre Study to assess efficacy and safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and Fluticasone Propionate FP)/Salmeterol Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents.Persistent Asthma10006436AsthmaNL-OMON34054GlaxoSmithKline62
进行中（未招募）
1 期
A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Multicentre Study to assess efficacy and safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and Fluticasone Propionate FP)/Salmeterol Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents.Persistent Asthma in Adults and Adolescents.MedDRA version: 12.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2010-019589-10-NLGlaxoSmithKline Research & Development Ltd1,564